Premium
Interaction between neuropeptide Y (NPY) and brain‐derived neurotrophic factor in NPY‐mediated neuroprotection against excitotoxicity: a role for microglia
Author(s) -
Xapelli S.,
Bernardino L.,
Ferreira R.,
Grade S.,
Silva A. P.,
Salgado J. R.,
Cavadas C.,
Grouzmann E.,
Poulsen F. R.,
Jakobsen B.,
Oliveira C. R.,
Zimmer J.,
Malva J. O.
Publication year - 2008
Publication title -
european journal of neuroscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.346
H-Index - 206
eISSN - 1460-9568
pISSN - 0953-816X
DOI - 10.1111/j.1460-9568.2008.06172.x
Subject(s) - neuroprotection , neuropeptide y receptor , ampa receptor , tropomyosin receptor kinase b , endocrinology , agonist , excitotoxicity , medicine , brain derived neurotrophic factor , chemistry , glutamate receptor , neurotrophic factors , microglia , nbqx , biology , receptor , neuropeptide , inflammation
The neuroprotective effect of neuropeptide Y (NPY) receptor activation was investigated in organotypic mouse hippocampal slice cultures exposed to the glutamate receptor agonist α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA). Exposure of 2‐week‐old slice cultures, derived from 7‐day‐old C57BL/6 mice, to 8 µ m AMPA, for 24 h, induced degeneration of CA1 and CA3 pyramidal cells, as measured by cellular uptake of propidium iodide (PI). A significant neuroprotection, with a reduction of PI uptake in CA1 and CA3 pyramidal cell layers, was observed after incubation with a Y 2 receptor agonist [NPY(13‐36), 300 n m ]. This effect was sensitive to the presence of the selective Y 2 receptor antagonist (BIIE0246, 1 µ m ), but was not affected by addition of TrkB‐Fc or by a neutralizing antibody against brain‐derived neurotrophic factor (BDNF). Moreover, addition of a Y 1 receptor antagonist (BIBP3226, 1 µ m ) or a NPY‐neutralizing antibody helped to disclose a neuroprotective role of endogenous NPY in CA1 region. Cultures exposed to 8 µ m AMPA for 24 h, displayed, as measured by an enzyme‐linked immunosorbent assay, a significant increase in BDNF. In such cultures there was an up‐regulation of neuronal TrkB immunoreactivity, as well as the presence of BDNF‐immunoreactive microglial cells at sites of injury. Thus, an increase of AMPA‐receptor mediated neurodegeneration, in the mouse hippocampus, was prevented by neuroprotective pathways activated by NPY receptors (Y 1 and Y 2 ), which can be affected by BDNF released by microglia and neurons.